Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28275876 | 0.78 | ALDH1A1 (0.48) | CYP3A4CYP1A2CYP1A1CYP1B1CA12 | |
| SCHEMBL6850895 | 0.76 | MAPT (0.42) | MAPTNPSR1POLBL3MBTL1CYP3A4 | |
| SCHEMBL11569140 | 0.76 | POLB (0.32) | MAPTNPSR1POLBL3MBTL1CYP3A4 | |
| SCHEMBL7818774 | 0.76 | ALDH1A1 (0.53) | MAPTNPSR1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL27743867 | 0.74 | MAPT (0.38) | MAPTNPSR1CYP3A4CYP1A2ACHE | |
| SCHEMBL210358 | 0.72 | ACHE (0.59) | MAPTL3MBTL1CYP3A4CYP1A2CYP1A1 | |
| SCHEMBL5231249 | 0.72 | RXFP1 (0.41) | MAPTNPSR1CYP3A4ACHECA12 | |
| SCHEMBL5623782 | 0.71 | ENPP2 (0.39) | MAPTCYP3A4CNKSR1CA1CA2 | |
| SCHEMBL2388340 | 0.70 | MAPT (0.46) | MAPTNPSR1POLBL3MBTL1CYP3A4 | |
| SCHEMBL1458153 | 0.70 | GAA (0.38) | MAPTNPSR1CYP3A4ACHECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403250-B1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-6787653-B2 | REACTING, IN THE PRESENCE OF A METAL CATALYST, A HALOGENOBENZOIC ACID DERIVATIVE WITH BENZENE DERIVATIVE TO PRODUCE BIPHENYLDICARBOXYLIC ACID AMIDE DERIVATIVE | KOWA CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| EP-1403250-A1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| WO-2003104213-A1 | PREPARATION PROCESS OF BIPHENYLCARBOXYLIC ACID AMIDE DERIVATIVES | KOWA CO., LTD. (JP) | 2003-12-18 | — | — | WO | disclosed |
| US-20030232992-A1 | Preparation process of biphenylcarboxylic acid amide derivatives | KOWA CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | H1-0, BRD4, PAH | MAPT 4297/4885NPSR1 740/4885POLB 2903/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | MAPT 3926/4885NPSR1 363/4885POLB 1554/4885 |
| US-20030232992-A1 | Preparation process of biphenylcarboxylic acid amide derivatives | CD22, C9, FCGR1A | MAPT 3568/4885NPSR1 2224/4885POLB 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.